Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Edith Biggers

General Practice Atlanta, GA Medical Doctor

NPI 1992882914 CMS profile 226466

99 Jesse Hill Jr Dr Room 234, Fulton County Dept Of Health & Wellness, Atlanta, GA 30303

Open in the dashboard

General payments

$3,534

117 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Edith Biggers of Atlanta, GA is reported in the CMS Open Payments database as having received $3,534 across 117 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of General Practice profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $157 10
2023 General $149 11
2022 General $310 27
2021 General $515 27
2020 General $495 16
2019 General $1,908 26

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Edith Biggers
  • General Practice median
  • Middle half of General Practice
  • National median

In program year 2025, general payments to Edith Biggers were reported at $157. Among 4,774 General Practice profiles paid that year, the median was $106 and the middle half received between $35 and $292.

Show as a table
Year Edith Biggers General Practice median Middle half National median
2019 $1,908 $107 $37–$285 $163
2020 $495 $75 $25–$213 $114
2021 $515 $93 $30–$272 $132
2022 $310 $103 $36–$279 $149
2023 $149 $106 $34–$276 $160
2024 $0 $114 $39–$290 $164
2025 $157 $106 $35–$292 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. ViiV Healthcare Company $1,216 48 payments
  2. Gilead Sciences, Inc. $1,056 26 payments
  3. Janssen Products, LP $629 6 payments
  4. Janssen Biotech, Inc. $430 33 payments
  5. Merck Sharp & Dohme Corporation $171 2 payments
  6. Janssen Pharmaceuticals, Inc $28 1 payment
  7. Janssen Scientific Affairs, LLC $4 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,307 114 payments
  2. Education $227 3 payments
Products named General payments · program years 2019–2025
  1. SYMTUZA $1,110 42 payments
  2. DOVATO $715 34 payments
  3. CABENUVA Hiv $253 3 payments
  4. Biktarvy $229 2 payments
  5. DELSTRIGO $171 2 payments
  6. TIVICAY $141 6 payments
  7. CABENUVA Hiv $129 8 payments
  8. JULUCA $43 5 payments
  9. TRIUMEQ $14 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

899

Median for General Practice: 1,105

Drug cost

$2,822,031

Median for General Practice: $48,734

Branded share of claims

89.2%

Median for General Practice: 17.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Biktarvy Bictegrav/Emtricit/Tenofov Ala Brand 279 $1,122,276
Genvoya Elviteg/Cob/Emtri/Tenof Alafen Brand 152 $602,210
Juluca Dolutegravir/Rilpivirine Brand 165 $594,886
Symtuza Darunavir/Cob/Emtri/Tenof Alaf Brand 49 $226,436
Dovato Dolutegravir Sodium/Lamivudine Brand 32 $96,800
Descovy Emtricitabine/Tenofov Alafenam Brand 28 $63,686
Tivicay Dolutegravir Sodium Brand 19 $42,202
Prezcobix Darunavir/Cobicistat Brand 14 $34,564
Edurant Rilpivirine Hcl Brand 11 $18,556
Darunavir Generic 16 $17,901

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,210 Part D prescribers listed as General Practice; they describe a distribution and say nothing about conduct.

Records

117 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other General Practice in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record